Effects of inhibition of the renin-angiotensin system on the cardiovascular actions of insulin

Diabetes, Obesity and Metabolism

Volumn 2, Issue 1, 2000, Pages 3-14

  Katovich, Michael J ^a,b   Pachori, Alok ^a  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

^b Department of Pharmaceutical Sciences and Experimental Therapeutics   (United States)

Author keywords

Angiotensin; Angiotensin receptor antagonist; Atherosclerosis; Converting enzyme inhibitor; Glucose tolerance; Hyperinsulinemia; Hyperttension; Insulin resistance; Renin angiotensin system

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BENAZEPRIL; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN HEXETIL; CAPTOPRIL; DELAPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FOSINOPRIL; GLUCOSE; INSULIN; LOSARTAN; PERINDOPRIL;

ADRENERGIC SYSTEM; ATHEROSCLEROSIS; BLOOD PRESSURE; CARDIOVASCULAR SYSTEM; CONTROLLED STUDY; GLUCOSE TOLERANCE; HORMONE ACTION; HUMAN; HYPERINSULINEMIA; HYPERTENSION; INSULIN RELEASE; INSULIN RESISTANCE; NATRIURESIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOGENESIS; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; VASCULAR SMOOTH MUSCLE;

EID: 0034524875     PISSN: 14628902     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1463-1326.2000.00044.x     Document Type: Review

References (120)

1. Hyperinsulinemia: A link between hypertension, obesity, and glucose intolerance
2. Essential hypertension, metabolic disorders, and insulin resistance
3. Insulin, insulin sensitivity and hypertension
4. Insulin resistance and hyperinsulinemia in hypertension
5. Insulin resistance, hyperinsulinemia, and hypertriglyceridemia in the etiology and clinical course of hypertension
6. Insulin and hypertension
7. Hyperinsulinemia, insulin resistance, and hyperglycemia: Contributing factors in the pathogenesis of hypertension and atherosclerosis
8. Role of insulin resistance and hyperinsulinemia in development of hypertension and atherosclerosis
9. Insulin resistance, glucose intolerance and hyperinsulinemia in patients with hypertension
10. Insulin resistance: A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease
11. Mechanisms of obesity-related Hypertension: Role of insulin and catecholamines
12. Effect of graded doses ofsulin on splanchnic and peripheral potassium metabolism in man
13. Insulin and renal sodium handling: Clinical implications
14. Sodium retention accompanying insulin treatment of diabetes mellitus
15. Effect of insulin and glucose infusions on sympathetic activity in normal man
16. Sympathetic response to oral carbohydrate administration: Evidence from micro-electrode nerve recordings
17. Obesity, metabolism, and the sympathetic nervous system
18. The sympathetic response to euglycaemic hyperinsulinemia
19. The relationships of abdominal obesity hyperinsulinemia and saturated fat intake to serum lipid levels: The Normative Aging Study
20. Interaction between insulin and AT1 receptor: Relevance for Hypertension and arteriosclerosis
21. Atherosclerosis and the arterial smooth muscle cell
22. Effect oftra-arterial insulin on tissue cholesterol and fatty acid synthesis in alloxan diabetic dogs
23. Characterisation ofduction of protooncogene C-MYC and cellular growth in human vascular smooth muscle cells by insulin and IGF-1
24. Effect of insulin and glucagon on production of renin substrate by the isolated rat liver
25. Insulin influences the renin-angiotensin-aldosterone system in humans
26. Altered regulation of renin secretion by insulin like growth factors and angiotensin II in diabetic rats
27. Downregulation of the renin-angiotensin system in streptozotocin-diabetic rats
28. Reduced proximal tubule angiotensin receptor expression in streptozotocin-induced diabetes mellitus
29. Reduced glomerular angiotensin II receptor density in early untreated diabetes in the rat
30. Is hypertension an insulin-resistant state? Metabolic changes associated with hypertension and antihypertensive therapy
31. Skeletal muscle blood flow: A possible link between insulin resistance and blood pressure
32. Decreased effect ofsulin to stimulate skeletal muscle blood flow in obese men: A novel mechanism for insulin resistance
33. Beneficial effects of angiotensin converting enzyme inhibitor on renal function and glucose homeostasis in diabetics with hypertension
34. Serum angiotensin converting enzyme in diabetic patients
35. Increase in serum angiotensin converting enzyme activity after oral glucose loading
36. Effects of angiotensin receptor antagonist and angiotensin converting enzyme inhibitor on insulin sensitivity in fructose-fed hypertensive rats and essential hypertensives
37. Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at mutipile levels
38. Effect of captopril, Losartan, and bradykinin on early steps of insulin action
39. Angiotensin receptor blockade blunts hyperinsulinemia-induced hypertension in rats
40. Role of angiotensin II in hyperinsulinemia-induced Hypertension in rats
41. Blockade of angiotensin II receptors inhibits the increae in blood pressure induced by insulin
42. Pressor doses of angiotensin II increase insulin-mediated glucose uptake in normontensive men
43. Maintenance of baseline angiotensin II potentiates insulin hypertension in rats
44. Angiotensin II affects basal, pulsatile, and glucose stimulated insulin secretion in humans
45. Low dose angiotensin-II increases glucose disposal rate during euglycemic hyperinsulinemia
46. Vascular renin-angiotensin system and sympathetic nervous system activity in human hypertenison
47. Effects of angiotensin II on insulin sensitivity and fasting glucose metabolism in rats
48. Hyperglycemic action of angiotensin II in freely moving rats
49. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism on patients with Hypertension
50. Insulin resistance in secondary hypertension
51. Insulin and blood pressure regulation
52. Resistance to insulin stimulated glucose uptake in patients with hypertension
53. Effect of weight loss without salt restriction on the reduction of blood pressure in overweight hypertensive patients
54. Anteroventral third ventricle lesions abolish lumbar sympathetic response to insulin
55. Central site for pressor action of blood-borne angiotensin in rat
56. Chronic hyperinsulinemia and blood pressure: Interaction with catecholamines?
57. Changes in renal function in essential hypertension
58. The effect of weight loss on the sensitivity of blood pressure to sodium in obese adolescents
59. Anti-hypertensive effect of insulin reduction in diabetic-hypertensive patients
60. Increased proximal tubular sodium reabsorption in Hyper-tensionive patients with type II diabetes
61. Endogenous angiotensin II inhibits natriuresis after acute, expansion in the neonatal rat
62. Insulin as a vascular hormone: Implications for the pathophysiology of cardiovascular disease
63. Cardiovascular actions of insulin: Are they important in long-term blood pressure regulation?
64. Beta adrenergic-mediated vasodilator response to insulin in the human forearm
65. Insulin-induced vasodilatation: Physiology or pharmacology?
66. Insulin resistance in hypertension: A focused review
67. 1 receptor gene expression by posttranscriptional mechanisms
68. Relation of pressor responsiveness to angiotensin II and insulin resistance in hypertension
69. Characterization of induction of protooncogene c-myc and cellular growth in human vascular smooth muscle cells by insulin and IGF-1
70. Effect ofsulin on the proliferation of cultured primate arterial smooth muscle cells
71. Effect of AT1 angiotensin-receptor blockade on structure and function of small arteries in SHR
72. Receptors and growth promoting effects of insulin and insulin like growth factors in cells from bovine retinal capillaries and aorta
73. Angiotensin II-induced proliferation of aortic myocytes in spontaneously hypertensive rats
74. 2 antagonists
75. The angiotensin-II receptor antagonist, losartan, inhibits LDL lipid peroxidation and atheroclerosis in apolipo-protein E-deficient mice
76. Angiotensin, LDL peroxidation and atherosclerosis
77. Effects of irbesartan and losartan administered peripherally or centrally on vasopressin release, drinking response, and c-fos expression in the rat brain
78. Prevention of intimal thickening after endothelial removal by a nonpeptide angiotensin II receptor antagonist, losartan
79. The coronary artery disease paradox: The role of hyperinsulinemia and insulin resistance and implications for therapy
80. Hypertension therpy and risk of coronary heart disease: How do antihypertensives affect metabolic factors?
81. Excess mortality associated with diuretic therapy in diabetes mellitus
82. Effects of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension
83. Effect of angiotensin converting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPP) randomised trial
84. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39
85. The calcium messenger system
86. The role of calcium ion as a mediator of the effects of angiotensin II, catecholamines, and vasopressin on the phosphorylation and activity of enzymes in isolated hepatocytes
87. Altered action of angiotensin II in patients with type 2 diabetes mellitus of recent onset
88. Losartan mediated improvement in insulin action is mainly due to an increase in non-oxidative glucose metabolism and blood flow in insulin-resistant hypertensive patients
89. Effect of chronic losartan potassium treatment on fructose-induced hypertension
90. Effect of fructose-induced hypertension on the renin-angiotensin-aldosterone system and atrial natriuretic factor
91. Vanadyl sulfate prevents fructose-induced hyperinsulinemia and hypertension in rats
92. Fructose-induced insulin resistance and hypertension in rats
93. Attenuation of fructose-induced hypertension in rats by exercise training
94. Somatostatin inhibition of fructose-induced hypertension
95. Role of angiotensin II in high fructose-induced left ventricular hypertrophy in rats
96. Relationship between blood pressure, plasma insulin and triglyceride concentration, and insulin action in spontaneous hypertensive and Wistar-Kyoto rats
97. Effect of acute and chronic losartan treatment on glucose tolerance and insulin sensitivity in fructose-fed rats
98. Kinin does not contribute to the improvement of insulin sensitivity in delapril treated fructose fed rats
99. Kinins contribute to the improvement of insulin sensitivity during treatment with angiotensin converting enzyme inhibitor
100. Effect on insulin sensitivity of angiotensin converting enzyme inhibitors with or without a sulphydryl group: Bradykinin may improve insulin resistance in dogs and humans
101. Vascular reactivity to phenylephrine and angiotensin II in hypertensive rats associated with insulin resistance
102. 1 receptor density changes during development of hypertension in hyperinsulinemic rats
103. Fructose feeding in rats is not associated with sodium retention
104. Effects of losartan on blood pressure, metabolic alterations, and vascular reactivity in the fructose-induced hypertensive rat
105. Vascular insulin resistance in fructose-hypertensive rats
106. PI3 kinase activation is required for insulin stimulation of pp 70 S6 kinase, DNA synthesis and glucose transport translocation
107. Inhibition of the translocation of Glut 1 and Glut 4 in 3T3 LI cells by PI3-kinase inhibitor, wortamnnin
108. Role of PI3 kinase in insulin receptor signaling: Studies with inhibitor LY294002
109. Serine/threonine phosphorylation of insulin receptor substrate1 modulates insulin receptor signaling
110. Phosphorylation ofsulin receptor substrate 1 on multiple serine residues, 612, 632, 662, and 731, modulates insulin action
111. Phorbol ester-induced serine phosphorylation of the insulin receptor decreases its tyrosine kinase activity
112. Crosstalk between the insulin and angiotensin signaling systems
113. Inhibition of angiotensin type 1 receptor prevents decline of glucose transporter (Glut 4) in diabetic rat heart
114. The effects on angiotensin II receptor antagonism with losartan on glucose metabolism and insulin sensitivity
115. A comparison of the hypotensive and hypoglycaemic actions of an angiotensin converting enzyme inhibitor, an AT1a antagonist and troglitazone
116. Effects of angiotensin II receptor blockade with losartan on insulin sensitivity, lipid profile, and endothelin in normotensive offspring of hypertensive parents
117. Effects of an angiotensin II receptor antagonist, TCV-116, on insulin sensitivity in fructosefed rats
118. Blockade of angiotensin converting enzyme but not of angiotensin AT1 receptors improves glucose tolerance
119. ACE inhibition but not angiotensin II antagonism reduces plasma fibrinogen and insulin resistance in overweight hypertensive patients
120. Captopril does not improve insulin action in essential hypertension: A double blind placebo-controlled study